title: New drugs and indications in 2012. Sluggish progress, timid measures to protect patients.
abstract: The therapeutic advances identified in 2012 were minimal, and 15 new drugs or indications are dangerous. The dearth of improvement in patient care contrasts with the sometimes disproportionately high prices agreed upon for drugs, especially in oncology. The few steps taken by health authorities that benefited patients, mainly by withdrawing or revoking reimbursement for drugs with an unfavourable harm-benefit balance, were insufficient in view of the constant pressure from the pharmaceutical industry to sell ever more drugs.
mesh_terms: D017277:Drug Approval / Q000191:economics / Q000331:legislation & jurisprudence*; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence*; D064420:Drug-Related Side Effects and Adverse Reactions; D005602:France; D006801:Humans; D007880:Legislation, Drug; D004364:Pharmaceutical Preparations / Q000008:administration & dosage* / Q000191:economics; D056737:Safety-Based Drug Withdrawals / Q000331:legislation & jurisprudence
chemical_list: D004364:Pharmaceutical Preparations